# A novel murine model of Sjögren’s disease using lacrimal autoantigen

**Authors:** Siyuan Li, Shan Liu, Yaqiong Li, Peng Zhang, Fengyang Lei, Lei Tian, Ying Jie

PMC · DOI: 10.3389/fimmu.2026.1586519 · Frontiers in Immunology · 2026-02-13

## TL;DR

This study creates a new mouse model for Sjögren’s disease that focuses on the lacrimal glands, mimicking key symptoms like dry eye and immune responses seen in the disease.

## Contribution

The study introduces a novel lacrimal gland-specific autoimmune model for Sjögren’s disease using lacrimal gland proteins.

## Key findings

- LGSS mice showed reduced tear and saliva secretion, lymphocyte infiltration, and elevated autoantibody levels.
- RNA sequencing revealed shared and unique gene expression patterns in LGSS mice compared to existing SjD models.
- The model exhibited Th1 and Th17 cell increases and ocular surface damage, making it suitable for studying SjD-DE.

## Abstract

Sjögren’s disease (SjD) is a group of chronic autoimmune diseases primarily targeting exocrine glands, including the lacrimal glands (LG). Involvement of the lacrimal glands leads to severe dry eye, also known as Sjögren’s disease-associated dry eye (SjD-DE). Current, available animal models of SjD are achieved by using autoantigens from salivary gland. This study establishes a novel lacrimal gland-specific autoimmune model that recapitulates key features of SjD-DE, providing a tool for investigating LG-focused mechanisms in SjD.

To establish the lacrimal gland-specific Sjögren’s model (termed LGSS) model, autoimmune responses were induced in mice using homogenized lacrimal gland proteins. LGSS mice were evaluated at various timepoints after immunization to determine SjD development. SjD phenotype such as tear and saliva secretion, lymphocyte infiltration in the lacrimal and salivary glands and serum autoantibody levels was assessed. Immune cell profiles in the spleen and cervical lymph nodes were evaluated via flow cytometry. In addition, corneal epithelial intactness, goblet cell density, lacrimal gland injury was evaluated to assess lacrimal gland involvement and secondary ocular surface damage. RNA sequencing and gene enrichment analysis of diseased lacrimal glands were performed.

LGSS mice demonstrated a reduced tear and saliva secretion, increased lymphocyte infiltration, and elevated autoantibody levels that are similar to common SjD mice. Additionally, the established LGSS mice demonstrated increased populations of Th1 and Th17 cell, along with lacrimal gland and ocular surface damage. RNA sequencing revealed that LGSS mice shared a common genetic profile with NOD mice, the spontaneous SjD model, such as Parp9, Cdkn2c, and Ifi35. Additionally, LGSS mice exhibited several uniquely expressed genes, including metabolism-related genes (Cbs, Dlst, Sardh) and genes associated with cellular processes (Actc1, Tnnc1).

The LGSS mice have been shown that successfully replicates several key features of SjD and demonstrates significant lacrimal gland and ocular surface damages, making it a valuable animal model to study SjD-DE.

## Linked entities

- **Genes:** PARP9 (poly(ADP-ribose) polymerase family member 9) [NCBI Gene 83666], CDKN2C (cyclin dependent kinase inhibitor 2C) [NCBI Gene 1031], IFI35 (interferon induced protein 35) [NCBI Gene 3430], CBS (cystathionine beta-synthase) [NCBI Gene 875], DLST (dihydrolipoamide S-succinyltransferase) [NCBI Gene 1743], SARDH (sarcosine dehydrogenase) [NCBI Gene 1757], ACTC1 (actin alpha cardiac muscle 1) [NCBI Gene 70], TNNC1 (troponin C1, slow skeletal and cardiac type) [NCBI Gene 7134]
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Ssb (small RNA binding exonuclease protection factor La) [NCBI Gene 20823] {aka SS-B}, Aqp5 (aquaporin 5) [NCBI Gene 11830], Actc1 (actin, alpha, cardiac muscle 1) [NCBI Gene 11464] {aka Actc-1}, Foxp3 (forkhead box P3) [NCBI Gene 20371] {aka JM2, scurfin, sf}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Cd3e (CD3 antigen, epsilon polypeptide) [NCBI Gene 12501] {aka CD3, CD3epsilon, T3e}, Ifi35 (interferon-induced protein 35) [NCBI Gene 70110] {aka 2010008K16Rik, IFP35, ifi-35}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Tnnc1 (troponin C, cardiac/slow skeletal) [NCBI Gene 21924] {aka TnC, cTnC, cTnI, tncc}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Dlst (dihydrolipoamide S-succinyltransferase) [NCBI Gene 78920] {aka 1600017E01Rik, 4632413C10Rik, 4930529O08Rik, DLTS}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 17395] {aka B/MMP9, Clg4b, Gel B, MMP-9, pro-MMP-9}, Cdkn2c (cyclin dependent kinase inhibitor 2C) [NCBI Gene 12580] {aka INK4c, p18, p18-INK4c, p18-INK6, p18INK4c}, Il2ra (interleukin 2 receptor, alpha chain) [NCBI Gene 16184] {aka CD25, Il2r, Ly-43}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Cbs (cystathionine beta-synthase) [NCBI Gene 12411] {aka HIP4}, Chrm3 (cholinergic receptor, muscarinic 3, cardiac) [NCBI Gene 12671] {aka Chrm-3, M3, M3R}, Acta2 (actin alpha 2, smooth muscle, aorta) [NCBI Gene 11475] {aka 0610041G09Rik, Actvs, SMAalpha, SMalphaA, a-SMA, alphaSMA}, Parp9 (poly (ADP-ribose) polymerase family, member 9) [NCBI Gene 80285] {aka ARTD9, Bagl, Bal, PARP-9}, Ro60 (Ro60, Y RNA binding protein) [NCBI Gene 20822] {aka 1810007I17Rik, A530054J02Rik, SS-A/Ro, Ssa, Ssa2, Trove2}, Trim21 (tripartite motif-containing 21) [NCBI Gene 20821] {aka Ro52, Ssa1}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Sardh (sarcosine dehydrogenase) [NCBI Gene 192166]
- **Diseases:** sialadenitis (MESH:D012793), insulin-dependent diabetes (MESH:D003922), tear volume loss (MESH:C000721448), ADDE (MESH:D015352), LGSS (MESH:C548032), photophobia (MESH:D020795), corneal epithelial damage (MESH:D009375), blindness (MESH:D001766), tear deficiency (MESH:D012167), non- (MESH:C580335), DE (MESH:D003635), lacrimal and salivary gland dysfunction (MESH:C562407), gland (MESH:D000307), autoimmune (MESH:D001327), NOD (MESH:D020191), irritation (MESH:D001523), ocular surface damage (MESH:D010534), diabetes (MESH:D003920), SjD (MESH:D012859), pain (MESH:D010146), corneal (MESH:D003316), inflammation (MESH:D007249), neurotrophic impairment (MESH:D009133), fibrosis (MESH:D005355)
- **Chemicals:** DAPI (MESH:C007293), PBS (MESH:D007854), paraformaldehyde (MESH:C003043), cobalt (MESH:D003035), fluorescein (MESH:D019793), pilocarpine hydrochloride (MESH:D010862), Cy7 (-), phenol red (MESH:D010637), Trizol (MESH:C411644), Cy5.5 (MESH:C098793), paraffin (MESH:D010232)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** /6.NOD — Mus musculus (Mouse), Induced pluripotent stem cell (CVCL_B3R1), /6N — Mus musculus (Mouse), Transformed cell line (CVCL_D461), C57BL/6.NOD — Homo sapiens (Human), Gastric adenocarcinoma, Cancer cell line (CVCL_VP28), C57BL/6N — Mus musculus (Mouse), Embryonic stem cell (CVCL_2H81)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12946062/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12946062/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12946062/full.md

---
Source: https://tomesphere.com/paper/PMC12946062